Inhibrx Biosciences

What Inhibrx Biosciences does

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company spun off from Inhibrx, Inc. in May 2024 following the sale of INBRX-101 to Sanofi. The company is headquartered in La Jolla, California, is publicly traded on NASDAQ under ticker INBX, and operates with 101-250 employees focused exclusively on oncology drug development. Its portfolio consists of two clinical-stage therapeutic candidates, both engineered using a proprietary single-domain antibody platform that enables the construction of multi-valent protein therapeutics with mechanisms of action not achievable with conventional bivalent antibodies. Ozekibart (INBRX-109) is a tetravalent DR5 agonist designed to induce tumor-selective apoptosis; INBRX-106 is a hexavalent OX40 agonist designed to promote hyperclustering of the OX40 costimulatory receptor for potent T-cell activation in combination with checkpoint inhibitors.

The company's primary indication is unresectable or metastatic conventional chondrosarcoma, a rare bone cancer with approximately 1,400 incident US cases annually and no currently approved systemic treatment. Ozekibart received FDA Orphan Drug and Fast Track designations, demonstrated a 52% reduction in disease progression risk in the ChonDRAgon registrational Phase 2 trial, and has a confirmed PDUFA goal date of April 14, 2027. Pipeline expansion efforts include colorectal cancer (ozekibart plus FOLFIRI, Phase 1/2), Ewing sarcoma, and first-line PD-L1 positive head and neck squamous cell carcinoma (INBRX-106 plus pembrolizumab, advancing to Phase 3 in Q3 2026).

The company is pre-commercial with no product revenue. Its business model centers on developing biologic therapeutics to regulatory approval and then commercializing through traditional pharmaceutical distribution channels (specialty pharmacies, hospital systems, oncology centers) in the United States. Inhibrx is funded through a $161.7M cash position supplemented by a March 2026 $75M debt facility from Oxford Finance LLC, against an annual net loss of approximately $140M. The company has attracted reported acquisition interest from Merck & Co., Merck KGaA, and Ono Pharmaceutical, with analyst projections valuing the ozekibart franchise at over $10 billion if clinical and commercial milestones are achieved.

Name

Inhibrx Biosciences

Legal name

Inhibrx Biosciences, Inc.

Website

https://inhibrx.com

Company type

Public

Founded year

2024

Operating status

Operating

Headcount range

101–250 employees

Short description

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing multi-valent biologic therapeutics for oncology, with lead candidate ozekibart in chondrosarcoma (FDA BLA accepted, PDUFA April 2027) and INBRX-106 advancing into Phase 3 for head and neck cancer.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Biologic therapeutics
• Oncology drug development
• Protein engineering
• Antibody therapeutics
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: The company is pre-commercial and does not yet generate product revenue. If ozekibart receives FDA approval, it would become Inhibrx's first commercial product and the first-ever FDA-approved systemic therapeutic for conventional chondrosarcoma.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of novel biologic therapeutic candidates for oncology and rare diseases using its proprietary single-domain antibody platform. Its lead candidates are ozekibart (INBRX-109), a tetravalent DR5 agonist targeting conventional chondrosarcoma, Ewing sarcoma, and colorectal cancer, and INBRX-106, a hexavalent OX40 agonist targeting head and neck squamous cell carcinoma and other solid tumors. The company is pre-revenue and preparing for potential FDA approval of ozekibart with a PDUFA goal date of April 14, 2027.

Product overview

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic therapeutics using its proprietary single-domain antibody platform. The company's pipeline consists of two clinical-stage therapeutic candidates: Ozekibart (INBRX-109), a tetravalent DR5 agonist targeting oncology indications including conventional chondrosarcoma, Ewing sarcoma, and colorectal cancer; and INBRX-106, a hexavalent OX40 agonist also targeting oncology. Both candidates leverage the company's protein-engineering expertise for differentiated mechanisms of action in cancer treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• Ozekibart (INBRX-109) Ozekibart is a clinical-stage tetravalent DR5 agonist therapeutic candidate precisely engineered using Inhibrx's single-domain antibody platform to achieve optimal balance of agonism and safety. It promotes tumor-biased programmed cell death by potently inducing DR5 receptor clustering while sparing normal tissues, and is being developed for conventional chondrosarcoma, Ewing sarcoma, and colorectal cancer indications.
• INBRX-106 INBRX-106 is a clinical-stage hexavalent OX40 agonist therapeutic candidate designed using Inhibrx's single-domain antibody platform to promote hyperclustering of the OX40 receptor, resulting in more potent activation of the OX40 costimulatory pathway and more robust antitumor activity than traditional bivalent therapeutic antibodies. It is being developed for first-line head and neck squamous cell carcinoma in combination with pembrolizumab.

Quantifiable outcome

• 52% reduction in risk of disease progression or death compared to placebo in ChonDRAgon trial
• +7 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered minor.

• ElpiScienceminorStrategic or Co-development PartnerElpiScience is listed as a partner on Inhibrx's investor relations page, indicating a collaborative relationship in the biopharmaceutical development space.
• RegeneronminorStrategic or Co-development PartnerRegeneron is listed as a partner on Inhibrx's investor relations page, indicating a collaborative relationship in the biopharmaceutical development space.
• CelgeneminorStrategic or Co-development PartnerCelgene is listed as a partner on Inhibrx's investor relations page, indicating a collaborative relationship in the biopharmaceutical development space.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Pyxis Oncology: Clinical-stage oncology biotech developing antibody-drug conjugates and immunotherapies. Similar company size, stage, and indication focus on solid tumors as Inhibrx Biosciences.
• Surface Oncology: Clinical-stage immunology/oncology biotech developing antibody-based immunotherapies including candidates targeting T-cell costimulatory pathways (OX40, CD39). Direct peer in IO biologics development.
• Intensity Therapeutics: Clinical-stage oncology company developing novel biologics in solid tumors. Comparable as a small clinical-stage developer actively working in OX40/immune agonist-adjacent oncology indications.
• MacroGenics: Clinical-stage oncology biologics company developing antibody-based therapeutics, including a tetravalent DART platform and DR5-targeting programs. Closely comparable to Inhibrx in both biologic drug-discovery approach and oncology indication focus.
• Mereo BioPharma: Clinical-stage biopharmaceutical company developing therapeutics for rare diseases and oncology. Comparable in stage and rare-disease oncology focus to Inhibrx's chondrosarcoma/sarcoma pipeline.
• Werewolf Therapeutics: Clinical-stage biotech developing conditionally activated biologic therapeutics for oncology. Comparable to Inhibrx as a small-cap clinical-stage oncology biologics developer pursuing differentiated mechanisms in solid tumors.
• Harpoon Therapeutics: Clinical-stage biotech developing T-cell engagers and immuno-oncology biologics using proprietary platform. Comparable in stage, scope, and therapeutic modality to Inhibrx's single-domain antibody platform approach.
• CytomX Therapeutics: Clinical-stage oncology company developing masked antibody therapeutics (Probody platform). Similar size, stage, and oncology biologics R&D model as Inhibrx, with comparable pipeline depth in solid tumors.

Broad incumbents

• Regeneron Pharmaceuticals: Large biotech with industry-leading antibody platform (VelocImmune) developing oncology biologics including checkpoint modulators. Listed as a partner on Inhibrx's investor page; broader scope and scale, but overlapping antibody-engineering domain.

Emerging players

• Compugen: Clinical-stage biotech using computational platforms to discover novel immuno-oncology targets and antibody therapeutics. Adjacent in stage and IO biologics focus to Inhibrx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/inhibrx
• Facebookfacebook.com/inhibrx
• LinkedInlinkedin.com/company/inhibrx

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inhibrx Biosciences